- Home
- EXEL vs SF Comparison
EXEL vs SF Comparison
Compare EXEL & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXEL | SF |
|---|---|---|
| Founded | 1994 | 1890 |
| Country | United States | United States |
| Employees | N/A | 9000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 11.4B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXEL | SF |
|---|---|---|
| Price | $44.47 | $78.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 7 |
| Target Price | $46.50 | ★ $90.33 |
| AVG Volume (30 Days) | ★ 2.1M | 1.2M |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.76% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $452,477,000.00 | N/A |
| Revenue This Year | $13.61 | $14.58 |
| Revenue Next Year | $13.13 | $8.03 |
| P/E Ratio | ★ $16.05 | $20.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.76 | $69.31 |
| 52 Week High | $48.74 | $134.74 |
Technical Indicators
Market Signals| Indicator | EXEL | SF |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 49.14 |
| Support Level | $40.98 | $75.78 |
| Resistance Level | $46.66 | $83.82 |
| Average True Range (ATR) | 1.37 | 2.47 |
| MACD | -0.13 | 0.33 |
| Stochastic Oscillator | 23.86 | 36.38 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.